Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Neurotrope BioScience completes $9.1mm Series A round; adds more funds to close round at $21.9mm

Executive Summary

Neurotrope BioScience Inc. (medicines and diagnostics for neurodegenerative disorders) raised $9.1mm in its Series A financing from 26 undisclosed investors. The 2012 start-up sold 9.1mm shares of Series A convertible preferred stock for $1.00. Neurotrope is beginning operations with worldwide rights to diagnostic and therapeutic technologies from the Blanchette Rockefeller Neurosciences Institute. The biotech hopes to launch in 2014 an early-stage AD detection test based on inflammation signaling in skin fibroblasts, followed four years later by an AD drug that activates protein kinase C-epsilon.

Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies